Milestone Pharmaceuticals has announced the commercial availability of CARDAMYST (etripamil) nasal spray in the United States, following approval by FDA in December 2025. The product is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults and is now available through U.S. retail pharmacies.

The company said it is implementing a commercialisation plan with a national sales force scheduled to launch in mid-February 2026. Milestone is also negotiating with insurers for formulary placement and coverage and has introduced a patient assistance platform to support access. For eligible commercially insured patients, copays are expected to be capped at $25.

Joseph Oliveto, president and chief executive officer of Milestone Pharmaceuticals, said: “Many patients have been waiting for help to take greater control of their PSVT condition. Now that CARDAMYST is available, patients have access to a convenient, self-administered option designed to treat episodes of PSVT wherever and whenever they occur.” He added: “Beyond availability, our team continues to engage insurers with the goal of having CARDAMYST widely covered and affordable.”

PSVT is a type of arrhythmia characterised by episodes of sudden-onset rapid heartbeats that can exceed 150 to 200 beats per minute. Symptoms include palpitations, shortness of breath, chest discomfort, dizziness and anxiety, which can significantly affect quality of life. Episodes may last for hours and often require emergency department visits or invasive procedures such as cardiac ablation.

Milestone said an estimated two million people in the United States are diagnosed with PSVT. The company noted that there has been limited innovation in treatment options for the condition, with CARDAMYST representing the first FDA-approved treatment for PSVT in more than 30 years.

The launch is supported by a patient assistance programme providing benefits verification, reimbursement support and copay assistance. The company said these measures are intended to reduce financial and administrative barriers to treatment while broader coverage negotiations continue.

While the announcement focuses on commercial rollout and access initiatives, the availability of a self-administered therapy could represent a shift in how acute PSVT episodes are managed, potentially reducing reliance on emergency care and invasive interventions.